<DOC>
	<DOCNO>NCT00598156</DOCNO>
	<brief_summary>Chemotherapy bevacizumab give 4 month . Patients progress continue maintenance treatment either bevacizumab ( Avastin ) alone , bevacizumab erlotinib ( Tarceva ) .</brief_summary>
	<brief_title>Chemotherapy Avastin Followed Maintenance Treatment With Avastin +/- Tarceva</brief_title>
	<detailed_description>Patients metastatic colorectal cancer treat standard chemotherapy accord investigator choice . In addition chemotherapy , Avastin ( bevacizumab ) give treatment period . After chemotherapy finish ( 18 week ) , maintenance therapy give patient randomize treatment either Avastin alone Avastin combination Tarceva ( erlotinib ) . Patients progressive disease , patient suitable curative resection metastasis take study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Adenocarcinoma colon rectum . 2 . Age &gt; 18 . 3 . Measurable disease accord RECIST criterion . 4 . Expected survival three month . 5 . Adequate bone marrow , liver kidney function . 6 . INR &lt; 1.5 time upper limit . 7 . Adequate contraception fertile patient . 8 . Signed write informed consent . 1 . Earlier chemotherapy metastatic colorectal cancer . 2 . Adjuvant treatment within 6 month . 3 . Surgery significant trauma within 28 day prior study entry . 4 . Planned radiotherapy target lesion . 5 . CNS metastases . 6 . Prior malignancy within 5 year except ca situ cervix basal cell carcinoma . 7 . Bleeding diathesis 8 . Uncontrolled hypertension . 9 . Significant cardiovascular disease . 10 . Treatment anticoagulant drug . 11 . Participation clinical trial . 12 . Pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>